Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP730515.RA_7wuVcgZzMJWAZ3nRCPd7pBRgXgbC_5kbkBPGAirawI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP730515.RA_7wuVcgZzMJWAZ3nRCPd7pBRgXgbC_5kbkBPGAirawI130_assertion type Assertion NP730515.RA_7wuVcgZzMJWAZ3nRCPd7pBRgXgbC_5kbkBPGAirawI130_head.
- NP730515.RA_7wuVcgZzMJWAZ3nRCPd7pBRgXgbC_5kbkBPGAirawI130_assertion description "[Therefore, in patients with CLL/SLL and rapidly enlarging asymmetric lymphadenopathy and/or extranodal tumors, we strongly advise FCM of fine-needle aspiration biopsy (FNAB) material, including CD62L, CD52, and CD71 analysis as well as assessment of karyotype and at least MYC abnormalities by FISH of the same FNAB material.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP730515.RA_7wuVcgZzMJWAZ3nRCPd7pBRgXgbC_5kbkBPGAirawI130_provenance.
- NP730515.RA_7wuVcgZzMJWAZ3nRCPd7pBRgXgbC_5kbkBPGAirawI130_assertion evidence source_evidence_literature NP730515.RA_7wuVcgZzMJWAZ3nRCPd7pBRgXgbC_5kbkBPGAirawI130_provenance.
- NP730515.RA_7wuVcgZzMJWAZ3nRCPd7pBRgXgbC_5kbkBPGAirawI130_assertion SIO_000772 25511139 NP730515.RA_7wuVcgZzMJWAZ3nRCPd7pBRgXgbC_5kbkBPGAirawI130_provenance.
- NP730515.RA_7wuVcgZzMJWAZ3nRCPd7pBRgXgbC_5kbkBPGAirawI130_assertion wasDerivedFrom befree-20150227 NP730515.RA_7wuVcgZzMJWAZ3nRCPd7pBRgXgbC_5kbkBPGAirawI130_provenance.
- NP730515.RA_7wuVcgZzMJWAZ3nRCPd7pBRgXgbC_5kbkBPGAirawI130_assertion wasGeneratedBy ECO_0000203 NP730515.RA_7wuVcgZzMJWAZ3nRCPd7pBRgXgbC_5kbkBPGAirawI130_provenance.